Preclinical Drug News
-
CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency
CD Formulation, a leading provider of contract pharmaceutical formulation development services, recently announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize the way medications are administered, enhancing efficiency and patient comfort. Microneedles are tiny, painless needles that penetrate the skin's ...
-
Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification
Creative Proteomics, a globally recognized leader in proteomics services, is excited to introduce its latest pioneering achievement in the field of membrane protein identification. This suite of solutions promises to reshape the scientific landscape, empowering researchers and scientists with advanced tools to unlock the secrets of membrane proteins. Membrane proteins, central to a wide range ...
-
CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
-
Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
-
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies. The Herpesviridae are a large family ...
-
CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...
-
Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. “We are thrilled to welcome Filippo to our executive team,” said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech. “Filippo’s extensive experience in ...
-
Six Signs your Clinical Development Leadership is Failing
Efficient leadership plays a huge role in bringing a clinical trial to fruition. Pharmaceutical companies are not immune to making mistakes and facing failures. Lack of funding, safety issues, and patient dropouts are some of the struggles clinical development teams face. Some problems you as a leader may face may not always be in your control, e.g., lack of funding. Other ...
By Brio Group
-
Endosomal Signaling Of Delta Opioid Receptors Is An Endogenous Mechanism And Therapeutic Target For Relief From Inflammatory Pain
Whether G protein-coupled receptors signal from endosomes to control important pathophysiological processes and are therapeutic targets is uncertain. We report that opioids from the inflamed colon activate δ-opioid receptors (DOPr) in endosomes of nociceptors. Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to ...
-
ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. Funds will advance development of ViGeneron’s next-generation ...
-
VeriSIM Life Secures a Federal Grant to Create a Drug Combinatorial Platform Against COVID-19
VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,908 to conduct research and development (R&D) work on rapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has developed a whole-body ...
By VeriSIM Life
-
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
By Bayer AG
-
Proteros receives minority investment from private equity firm Inflexion
Proteros biostructures GmbH, a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding. The transaction is subject to customary regulatory ...
-
Creative Proteomics Launches SPR-based Biacore Service to Help Study Biomolecular Interactions
Creative Proteomics is an integrated CRO company committed to providing a full range of services in order to support various proteomic research projects, covering the identification of single proteins to large-scale proteomic studies. The company introduces the high-quality Biacore service based on its powerful Surface Plasmon Resonance (SPR) technology for label-free and real-time analysis of ...
-
Beyond Cancer Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted ...
-
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...
-
Orion Receives Funding to Advance its Lead GPCR-Targeted Therapeutic
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The ...
-
Creative Proteomics Cytokine Announces the Launch of Chemokine Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Chemokines Detection Service to help thoroughly investigate the many types of chemokines induced by ...
-
Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes
Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and ...
-
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017. IND clearance enables Antengene to initiate the combination portion of the Phase I “ERASER” clinical trial in the United States (U.S.) to evaluate the safety, pharmacokinetics, and preliminary efficacy of ATG-017 combination therapy ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you